Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 20Neoplasm Metastasis 13Liver Neoplasms 8Colorectal Neoplasms 7Lung Neoplasms 6Cholangiocarcinoma 6Pancreatic Neoplasms 5Rectal Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Barrett Esophagus 4Recurrence 3Pain 3Biliary Tract Neoplasms 3Prostatic Neoplasms 2Leiomyoma 2Kidney Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms 2Thyroid Cancer, Papillary 1Thymoma 1Squamous Intraepithelial Lesions 1Small Cell Lung Carcinoma 1Pancreatic cancer, adult 1Neuroendocrine Tumors 1Neoplastic Cells, Circulating 1Neoplasms 1Neoplasm Micrometastasis 1Myoma 1

Interventions

Ipilimumab 12tremelimumab 6durvalumab 6Nivolumab 6pembrolizumab 4Paclitaxel 2Oxaliplatin 2Carboplatin 2Capecitabine 2Blood Specimen Collection 2spartalizumab 1relatlimab 1lenvatinib 1folfirinox 1Vaccines 1Radiotherapy 1Radiofrequency Ablation 1Radiation 1Opdualag 1Monophenol Monooxygenase 1Leucovorin 1Fluorouracil 1Docetaxel 1Cryosurgery 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Diabetes Mellitus, Insulin-Dependent, 12 × Radiofrequency Ablation × Clear all
NCT02821754 2023-03-28

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
54 enrolled 14 charts
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡